Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Imcheck Therapeutics SAS manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action for the company. This single action constitutes the current active prosecution workload for the organization.
The portfolio is being reviewed within 1 distinct art unit by 1 distinct examiner. This indicates that the company's current intellectual property efforts are not spread across multiple technical divisions. The 1 pending office action is the only point of contact with the patent office's examination staff at this stage.
ROONEY, NORA MAUREEN is the busiest examiner, with 1 busiest examiner pending office action. Since this examiner is the only one assigned to the portfolio, their individual examination patterns are the primary factor in current prosecution. The company's strategy is currently linked to the 1 distinct art unit where this examiner operates.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18183588 | SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18183588 | SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT | ROONEY, NORA MAUREEN | 1641 | §112DP | Non-Final OA | — | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial